NovAccess Global Inc
NovAccess Global Inc., a biopharmaceutical company, engages in the development of novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in New York, New York.
NovAccess Global Inc (XSNX) - Net Assets
Latest net assets as of September 2024: $-7.43 Million USD
Based on the latest financial reports, NovAccess Global Inc (XSNX) has net assets worth $-7.43 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($273.56K) and total liabilities ($7.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.43 Million |
| % of Total Assets | -2714.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 74.37 |
NovAccess Global Inc - Net Assets Trend (2004–2024)
This chart illustrates how NovAccess Global Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NovAccess Global Inc (2004–2024)
The table below shows the annual net assets of NovAccess Global Inc from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $-7.80 Million | 0.00% |
| 2023-09-30 | $-7.80 Million | -67.60% |
| 2022-09-30 | $-4.65 Million | -18.46% |
| 2021-09-30 | $-3.93 Million | -10.04% |
| 2020-09-30 | $-3.57 Million | -59.65% |
| 2019-09-30 | $-2.24 Million | +51.79% |
| 2018-09-30 | $-4.64 Million | -344.13% |
| 2017-09-30 | $-1.04 Million | -24.25% |
| 2016-09-30 | $-840.45K | +4.41% |
| 2015-09-30 | $-879.25K | +2.61% |
| 2014-09-30 | $-902.78K | -13.90% |
| 2013-09-30 | $-792.63K | -425.27% |
| 2012-09-30 | $-150.90K | +71.30% |
| 2011-09-30 | $-525.80K | -25.44% |
| 2010-09-30 | $-419.16K | -186.82% |
| 2009-09-30 | $482.81K | -91.11% |
| 2008-09-30 | $5.43 Million | 0.00% |
| 2007-09-30 | $5.43 Million | -13.76% |
| 2006-09-30 | $6.30 Million | +1282.19% |
| 2005-09-30 | $-532.55K | -2114.43% |
| 2004-09-30 | $-24.05K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NovAccess Global Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6461414100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $43.68 Million | % |
| Other Comprehensive Income | $-6.00 Million | % |
| Other Components | $21.42 Million | % |
| Total Equity | $-7.80 Million | 100.00% |
NovAccess Global Inc Competitors by Market Cap
The table below lists competitors of NovAccess Global Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pan-Pacific Co. Ltd.
KQ:007980
|
$12.38K |
|
New Green Hemp Inc.
PINK:GLFHD
|
$12.39K |
|
Faisal Spinning Mills Ltd
KAR:FASM
|
$12.40K |
|
MPX International Corp
PINK:MPXOF
|
$12.40K |
|
KEPL3F
SA:KEPL3F
|
$12.38K |
|
SIG plc
LSE:SHI
|
$12.37K |
|
Belmont Resources Inc
PINK:BELMF
|
$12.37K |
|
Hatton National Bank PLC
CM:HNBN0000
|
$12.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NovAccess Global Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -7,798,484 to -7,798,484, a change of 0.
- Net loss of 4,769,187 reduced equity.
- Share repurchases of 5,000 reduced equity.
- Other comprehensive income decreased equity by 6,000,000.
- Other factors increased equity by 10,774,187.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.77 Million | -61.16% |
| Share Repurchases | $5.00K | -0.06% |
| Other Comprehensive Income | $-6.00 Million | -76.94% |
| Other Changes | $10.77 Million | +138.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NovAccess Global Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-09-30 | $-477.74 | $0.00 | x |
| 2002-09-30 | $-539.33 | $0.00 | x |
| 2003-09-30 | $0.36 | $0.00 | x |
| 2004-09-30 | $-0.21 | $0.00 | x |
| 2005-09-30 | $-4.30 | $0.00 | x |
| 2006-09-30 | $50.83 | $0.00 | x |
| 2007-09-30 | $32.92 | $0.00 | x |
| 2008-09-30 | $39.34 | $0.00 | x |
| 2009-09-30 | $2.55 | $0.00 | x |
| 2010-09-30 | $-2.05 | $0.00 | x |
| 2011-09-30 | $-2.41 | $0.00 | x |
| 2012-09-30 | $-0.61 | $0.00 | x |
| 2013-09-30 | $-2.31 | $0.00 | x |
| 2014-09-30 | $-1.68 | $0.00 | x |
| 2015-09-30 | $-1.35 | $0.00 | x |
| 2016-09-30 | $-1.15 | $0.00 | x |
| 2017-09-30 | $-1.12 | $0.00 | x |
| 2018-09-30 | $-3.43 | $0.00 | x |
| 2019-09-30 | $-0.38 | $0.00 | x |
| 2020-09-30 | $-0.46 | $0.00 | x |
| 2021-09-30 | $-0.35 | $0.00 | x |
| 2022-09-30 | $-0.28 | $0.00 | x |
| 2023-09-30 | $-0.37 | $0.00 | x |
| 2024-09-30 | $-0.37 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NovAccess Global Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-354.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $342.18K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.88K |
| 2003 | -6209.79% | 0.00% | 0.00x | 1.00x | $-146.10K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.51 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.35 Million |
| 2006 | -54.67% | -43024.25% | 0.00x | 1.09x | $-4.07 Million |
| 2007 | -23.75% | -18742.69% | 0.00x | 1.06x | $-1.83 Million |
| 2008 | -23.75% | -18742.69% | 0.00x | 1.06x | $-1.83 Million |
| 2009 | -2202.55% | 0.00% | 0.00x | 2.85x | $-10.68 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.17 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.07 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.54 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.44 Million |
| 2014 | 0.00% | -495.50% | 5.67x | 0.00x | $-1.86 Million |
| 2015 | 0.00% | -108.64% | 12.81x | 0.00x | $-1.23 Million |
| 2016 | 0.00% | -32.36% | 11.39x | 0.00x | $-158.82K |
| 2017 | 0.00% | -42.51% | 24.29x | 0.00x | $-394.24K |
| 2018 | 0.00% | -596.89% | 4.31x | 0.00x | $-3.51 Million |
| 2019 | 0.00% | 145.70% | 7.48x | 0.00x | $2.57 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.44 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.12 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.25 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.99 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.99 Million |
Industry Comparison
This section compares NovAccess Global Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NovAccess Global Inc (XSNX) | $-7.43 Million | 0.00% | N/A | $12.38K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |